Log in to search using one of your social media accounts:


FDA Approves Landmark Cancer Therapy; Wilmot Positioned Among First to Offer It

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news

Related Links:

Conclusions: ALK inhibitors have an acceptable safety profile with a low risk of treatment-related deaths. Important differences in toxicity profile were detected amongst the different drugs. PMID: 29774128 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: We showed that the expression of BG4 in the gastric cancer cell line AGS inhibits cell proliferation and promotes apoptosis though inducing telomere to form G-quadruplex structure and attenuating telomerase activity, thus resulting in reduced expression of hTERT and Bcl-2. PMID: 29771410 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
In this study, we found discrepancies in iNKT cell responses against two T cell-origin cell lines (Jurkat and Molt-4). Human iNKT cells exhibited more intensive cytotoxicity and less efficient cytokine production in response to Fas-bearing Jurkat cells than those to the Fas-negative tumor cells (Molt-4 and myeloid-derived K562). The imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells were CD1d-dependent and relied mostly on Fas/FasL interaction. The impairment in cytokine production could be overcome by Fas/FasL blocking antibodies and exogenous IL-2. Elevated CD1d levels as well as CD1d and Fas c...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Our study was to examine the roles of crizotinib and ceritinib in hepatocellular carcinoma (HCC) cells and explore the possible mechanisms. MTT assay was employed to examine the proliferation of five HCC cell lines treated with various concentrations of crizotinib or ceritinib. HepG2 and HCCLM3 cells were incubated with 2 nmol/l ceritinib for 1 week, followed by crystal violet staining and cell counting. Protein amounts of t-ALK, p-ALK, t-AKT, p-AKT, t-ERK, p-ERK, Mcl-1, survivin, and XIAP in HepG2 cells under different culture conditions were evaluated by western blot. HepG2 and HCCLM3 cells were treated with vehic...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
According to 2010-2012 data from the National Cancer Institute (NCI), 40% of men and women will be diagnosed with cancer in their lifetime. In all its forms, cancer is known to be a clinically and emotionally challenging disease to manage. Despite th...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Exclusive Oncology Pathology Source Type: blogs
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials... Author: VJHemOnc Added: 05/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
CONCLUSION: Therapeutic strategies based on better molecular characterization of various histological types are certain to be used in the future. PMID: 29769011 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Authors: Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M Abstract Mean platelet volume (MPV) is reported to be associated with the risk of venous thromboembolism (VTE) and mortality in patients with cancer. We sought to determine the association of MPV with symptomatic VTE occurrence in patients treated for newly diagnosed Hodgkin lymphoma (HL) and their outcomes. We retrospectively studied 167 consecutive adult patients treated with HL. During first-line treatment 12 (7.2%) patients developed VTE and 14 (8%) died within the observation period. The pre-chemotherapy values of MPV were significantly lower...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Chukkapalli V, Gordon LI, Venugopal P, Borgia JA, Karmali R Abstract Metformin exerts direct anti-tumor effects by activating AMP-activated protein kinase (AMPK), a major sensor of cellular metabolism in cancer cells. This, in turn, inhibits pro-survival mTOR signaling. Metformin has also been shown to disrupt complex 1 of the mitochondrial electron transport chain. Here, we explored the lymphoma specific anti-tumor effects of metformin using Daudi (Burkitt), SUDHL-4 (germinal center diffuse large B-cell lymphoma; GC DLBCL), Jeko-1 (Mantle-cell lymphoma; MCL) and KPUM-UH1 (double hit DLBCL) cell lines. We ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, to the best of the authors' knowledge, this is the first study to investigate the effects of an anti‑proliferative peptide derived from Cyclina sinensis on DU‑145 cells, and the results suggested that CSP may represent a therapeutic nutraceutical agent for the treatment of patients with PCa. PMID: 29767237 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Lymphoma | Universities & Medical Training